Adverse events were mostly mild or moderate in severity and of short duration, according to the researchers
Slows Gastric Emptying The medication delays how quickly food leaves the stomach, promoting a sensation of fullness that supports portion control and reduces snacking behaviors
Friedrichsen et al., 2021), including 4,512 individuals, provided the proportion of participants with AEs and SAEs
According to primary trials in T2DM, tirzepatide significantly reduces clinical outcomes like body weight, glycated hemoglobin (HbA1c), lipid profiles, and glucose-adjusted glucagon secretion compared to typical glucagon-like peptide1 receptor agonists (GLP1RAs) [1, 2]
"I think that's just kind of physiology, that your body's only willing to go so far to shed the weight." Dr
Ma D, Liu X, Liu J, et al